Ahmedabad-based parenteral products manufacturer Amanta Healthcare is set to make its debut on Dalal Street with a fresh-issue Initial Public Offering (IPO) on September 1, 2025. The company has revised its offer size downward, opting for a more calibrated capital raise while maintaining its original expansion objectives. The IPO will be open for subscription until September 3, with allotment finalization expected on September 4 and listing scheduled for September 8 on both the BSE and NSE.
The IPO comprises a fresh issue of 1 crore equity shares, reduced from the previously proposed 1.25 crore shares as per the draft red herring prospectus filed in February. The trimmed offer size is estimated to be in the ₹130–160 crore range.
🧭 Key IPO Details and Timeline
| Event | Date/Details |
|---|---|
| IPO Opening Date | September 1, 2025 |
| IPO Closing Date | September 3, 2025 |
| Anchor Book Launch | August 29, 2025 |
| Allotment Finalization | September 4, 2025 |
| Listing Date | September 8, 2025 |
| Issue Type | 100% Fresh Issue |
| Total Shares Offered | 1 crore equity shares |
| Estimated Offer Size | ₹130–160 crore |
| Price Band | ₹120–126 per share |
| Minimum Lot Size | 119 shares (₹14,994) |
| Lead Manager | Beeline Capital Advisors |
| Registrar | MUFG Intime India |
The IPO will allocate up to 50% of the net issue to Qualified Institutional Buyers (QIBs), at least 35% to retail investors, and a minimum of 15% to Non-Institutional Investors (NIIs).
📊 Use of Proceeds: Expansion of Sterile Manufacturing Lines
Amanta Healthcare plans to utilize the IPO proceeds primarily for capital expenditure at its Hariyala facility in Gujarat. The company will invest ₹70 crore in civil construction and ₹30.13 crore in equipment and machinery for new manufacturing lines under its SteriPort brand (large volume parenterals) and SVP (small volume parenterals) segments.
| Investment Area | Allocation (₹ crore) | Purpose |
|---|---|---|
| Civil Construction | ₹70.00 | Infrastructure for new manufacturing lines |
| Equipment & Machinery | ₹30.13 | SteriPort and SVP production expansion |
| General Corporate Purposes | Balance amount | Operational flexibility and working capital |
The expansion is expected to enhance production capacity and support the company’s growing domestic and international demand for sterile liquid formulations.
🔍 Company Overview: Parenteral Expertise and Global Reach
Founded in 1994, Amanta Healthcare specializes in sterile liquid products including IV fluids, diluents, ophthalmic solutions, respiratory care products, and medical devices. The company operates seven manufacturing lines across large and small volume parenterals using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies.
| Segment | Product Types | Technology Used |
|---|---|---|
| Large Volume Parenterals | IV fluids, irrigation solutions | ABFS, ISBM |
| Small Volume Parenterals | Ophthalmics, respiratory care, eye lubricants | ABFS, ISBM |
| Medical Devices | First-aid solutions, eye care kits | Sterile packaging and molding |
Amanta markets over 45 generic products through 320 distributors in India and exports to 21 countries across Africa, Latin America, the UK, and other regions.
📉 Financial Performance: Profit Surge Despite Revenue Dip
Amanta Healthcare posted a 189% jump in net profit for FY25, reaching ₹10.5 crore compared to ₹3.63 crore in FY24. This growth was driven by reduced finance and depreciation costs, along with improved operating margins. However, revenue from operations declined 2% to ₹274.71 crore in FY25 from ₹280.34 crore in FY24.
| Financial Metric | FY24 (₹ crore) | FY25 (₹ crore) | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | ₹280.34 | ₹274.71 | -2.00% |
| EBITDA | ₹57.5 | ₹59.7 | +3.80% |
| EBITDA Margin (%) | 20.50% | 21.72% | +122 bps |
| Net Profit | ₹3.63 | ₹10.50 | +189.00% |
The company’s EBITDA margin expanded by 122 basis points, indicating operational efficiency improvements despite subdued topline performance.
🧠 Promoter Holding and Shareholding Structure
Promoters currently hold 85.6% of Amanta Healthcare, while the remaining 14.4% is owned by public shareholders, including alternative investment fund Finavenue Growth Fund.
| Shareholder Type | Holding (%) |
|---|---|
| Promoters | 85.6% |
| Public Shareholders | 14.4% |
Post-IPO, promoter holding is expected to dilute proportionally, enhancing public float and liquidity.
📌 Conclusion
Amanta Healthcare’s upcoming IPO on September 1 marks a significant milestone in its growth journey. With a reduced offer size and a clear focus on expanding sterile manufacturing capabilities, the company aims to strengthen its position in the parenteral products segment both in India and abroad.
Backed by strong fundamentals, advanced technology, and a robust distribution network, Amanta’s IPO offers investors an opportunity to participate in the growth of a niche healthcare manufacturer with global aspirations.
—
Disclaimer: This article is based on publicly available news reports and official statements as of August 25, 2025. It is intended for informational purposes only and does not constitute financial, legal, or investment advice.
